PRIMARY STUDY
(+)-trans-Cannabidiol-2-hydroxy pentyl is a dual CB 1 R antagonist/CB 2 R agonist that prevents diabetic nephropathy in mice
Key Findings: Both (+)-enantiomers of cannabidiol (CBD) in this mouse model show potential therapeutic use in metabolic and immune-related disorders such as Type-1 diabetes and diabetic kidney disease by targeting type 1 and type 2 CB receptors.
Type of Study: Animal Study
Study Result: Positive
Research Location(s): Germany, Spain
Year of Pub: 2021
Cannabinoids Studied: Cannabidiol (CBD)
Phytocannabinoid Source: Isolate
Chemotype: Chemotype III
Receptors Studied: CB1, CB2
Citation: González-Mariscal I, et al. (+)-trans-Cannabidiol-2-hydroxy pentyl is a dual CB1R antagonist/CB2R agonist that prevents diabetic nephropathy in mice. Pharmacol Res. 2021; 169:105492. doi: 10.1016/j.phrs.2021.105492
Authors: González-Mariscal I, Carmona-Hidalgo B, Winkler M, Unciti-Broceta JD, Escamilla A, Gómez-Cañas M, Fernández-Ruiz J, Fiebich BL, Romero-Zerbo SY, Bermúdez-Silva FJ, Collado JA, Muñoz E
